Genetics Generation Advancement Corp. Stock
Equities
4160
TW0004160007
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
53 TWD | -3.99% | +26.79% | +36.25% |
Sales 2022 | 548M 16.85M 22.99M | Sales 2023 | 592M 18.23M 24.86M | Capitalization | 988M 30.4M 41.47M |
---|---|---|---|---|---|
Net income 2022 | 25M 769K 1.05M | Net income 2023 | 28M 861K 1.17M | EV / Sales 2022 | 0.75 x |
Net cash position 2022 | 255M 7.85M 10.71M | Net cash position 2023 | 266M 8.17M 11.15M | EV / Sales 2023 | 1.22 x |
P/E ratio 2022 |
26.1
x | P/E ratio 2023 |
34.7
x | Employees | 104 |
Yield 2022 |
1.74% | Yield 2023 |
1.31% | Free-Float | 58.95% |
1 day | -3.99% | ||
1 week | +26.79% | ||
Current month | +25.30% | ||
1 month | +25.59% | ||
3 months | +27.40% | ||
6 months | +27.40% | ||
Current year | +36.25% |
Managers | Title | Age | Since |
---|---|---|---|
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Tai Sheng Chang
CTO | Chief Tech/Sci/R&D Officer | - | - |
Fang Chun Huang
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yue Jen Huang
BRD | Director/Board Member | - | 20-06-09 |
Cheng Hsien Tsai
CEO | Chief Executive Officer | - | - |
Wen Cheng Chang
BRD | Director/Board Member | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-28 | 53 | -3.99% | 547 143 |
24-04-26 | 55.2 | -0.18% | 1,073,018 |
24-04-25 | 55.3 | +9.94% | 790,476 |
24-04-24 | 50.3 | -0.40% | 1,093,370 |
24-04-23 | 50.5 | +9.90% | 1,218,704 |
End-of-day quote Taipei Exchange, April 28, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+36.25% | 42.99M | |
-20.36% | 10.82B | |
+48.28% | 3.25B | |
-32.92% | 2.11B | |
-14.15% | 2.08B | |
-26.03% | 1.48B | |
+19.62% | 1.02B | |
-2.62% | 733M | |
-31.88% | 391M | |
-43.78% | 383M |
- Stock Market
- Equities
- 4160 Stock